Fulcrum Therapeutics, Inc.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $7.8M
- Net income
- -$74.9M
- Total assets
- $366.3M
- Market cap
- $245.9M
- Operating margin
- -27.4%
- Net margin
- -12.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $80.0M
- Operating expenses
- $101.9M
- Operating income
- -$21.9M
- Net income
- -$9.7M
- EPS (basic)
- $-0.16
- EPS (diluted)
- $-0.16
Balance sheet
- Total assets
- $260.7M
- Current assets
- $249.9M
- Total liabilities
- $17.7M
- Current liabilities
- $11.0M
- Shareholders’ equity
- $243.0M
Cash flow
- Operating cash flow
- -$2.2M
- Investing cash flow
- $32.2M
- Financing cash flow
- $2.7M
- Net cash flow
- $32.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $245.9M
- EPS (diluted)
- $-0.16
- Shares outstanding
- 71.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 18, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.9M in FY2021.
- Revenue grew 807% from FY2020 to FY2024.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Fulcrum Therapeutics, Inc..
Write a review
News about Fulcrum Therapeutics, Inc.
News & sentiment via Polygon.io
